Evidence map›Paper›PMID 38895329›Full record

ArticlebioRxiv : the preprint server for biology2025

Multi-omic phenotyping of iPSC-derived neurons harboring the

Gregory A Mohl, Gary Dixon, Emily Marzette, Justin McKetney, Avi J Samelson, Carlota Pereda Serras, Julianne Jin, Nabeela Ariqat, Andrew Li, Steven C Boggess and 2 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Gregory A MohlInstitute for Neurodegenerative Diseases, University of California San Francisco, San Francisco, CA, USA.
Gary DixonInstitute for Neurodegenerative Diseases, University of California San Francisco, San Francisco, CA, USA.
Emily MarzetteInstitute for Neurodegenerative Diseases, University of California San Francisco, San Francisco, CA, USA.
Justin McKetneyGladstone Data Science and Biotechnology Institute, The J. David Gladstone Institutes, San Francisco, CA, USA.
Avi J SamelsonInstitute for Neurodegenerative Diseases, University of California San Francisco, San Francisco, CA, USA.
Carlota Pereda SerrasInstitute for Neurodegenerative Diseases, University of California San Francisco, San Francisco, CA, USA.
Julianne JinInstitute for Neurodegenerative Diseases, University of California San Francisco, San Francisco, CA, USA.
Nabeela AriqatInstitute for Neurodegenerative Diseases, University of California San Francisco, San Francisco, CA, USA.
Andrew LiInstitute for Neurodegenerative Diseases, University of California San Francisco, San Francisco, CA, USA.
Steven C BoggessInstitute for Neurodegenerative Diseases, University of California San Francisco, San Francisco, CA, USA.
Danielle L SwaneyGladstone Data Science and Biotechnology Institute, The J. David Gladstone Institutes, San Francisco, CA, USA.
Martin KampmannInstitute for Neurodegenerative Diseases, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-3819-7019

Funding

Project 3: Autophagy dysfunction and neuronal activity in FTDU54NS100717 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI CUERVO, ANA MARIA · 2016 to 2020
$10.8M
Uncovering the Genetic Mechanisms of the Chromosome 17q21.31 Tau Haplotype on Neurodegeneration Risk in FTD and PSPU54NS123746 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHANG, TIMOTHY S · 2021 to 2025
$9.4M
Systematic elucidation of endosomal trafficking as a therapeutic opportunity in AD using CRISPR-based functional genomicsR01AG062359 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KAMPMANN, MARTIN · 2018 to 2022
$3.2M
Molecular mechanisms of selective vulnerability of neurons to tauopathyR01AG082141 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CARLO L CONDELLO, Martin Kampmann · 2023 to 2026
$3.0M
Pharmaceutical Sciences and PharmacogenomicsT32GM142516 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Su Guo · 2022 to 2026
$2.4M
Functional Characterization of Tau Mutation and Post-translational ModificationsR00AG080116 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Avi Jacob Samelson · 2025 to 2026
$487k
Functional Characterization of Tau Mutation and Post-translational ModificationsK99AG080116 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SAMELSON, AVI JACOB · 2023 to 2024
$246k
Mechanisms of tau misfolding in neurons elucidated by deep mutational scanning and CRISPR screeningF32AG063487 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SAMELSON, AVI JACOB · 2019 to 2021
$195k
NIA NIH HHS F32 AG063487NIA NIH HHS K99 AG080116NIA NIH HHS R00 AG080116NIA NIH HHS R01 AG062359NIA NIH HHS R01 AG082141NIGMS NIH HHS T32 GM142516NINDS NIH HHS U54 NS100717NINDS NIH HHS U54 NS123746
6 · The paper itself

Abstract

Tau aggregation is a hallmark of several neurodegenerative diseases, including Alzheimer's disease and frontotemporal dementia. There are disease-causing variants of the tau-encoding gene,

Identifiers

PMID38895329
PMCPMC11185762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.